Welcome, Guest. Please login or register.
May 20, 2024, 11:06:27 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 87
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 69
Total: 69


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Hep C Pipeline update from AASLD  (Read 13823 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 187
Hep C Pipeline update from AASLD
« on: November 07, 2011, 09:43:04 am »
Hep EIC Tim Horn is in San Francisco at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). His first post is about the much anticipated interferon-free PSI-7977 regimen. The latest data shows a 100% cure rate in Hep C genotype 2/3. Wow!


Offline farmgirl

  • Member
  • Posts: 20
Re: Hep C Pipeline update from AASLD
« Reply #1 on: November 07, 2011, 03:43:16 pm »
100% cure rate sounds to good to be true has that ever happened before for any medicine?

Offline worriedsilly

  • Member
  • Posts: 12
Re: Hep C Pipeline update from AASLD
« Reply #2 on: November 08, 2011, 12:59:05 pm »
it was only 10 people!!! get back to me when it is hundreds

Offline curiousinsanjose

  • Member
  • Posts: 8
Re: Hep C Pipeline update from AASLD
« Reply #3 on: November 10, 2011, 10:52:14 am »
anotehr study was only 47 people? what gives. is that normally for drg trials to use so few people and consider the results 'good'

Offline Tim Horn

  • Member
  • Posts: 51
Re: Hep C Pipeline update from AASLD
« Reply #4 on: November 14, 2011, 10:35:50 am »
Keep in mind, A LOT of the data coming out of the AASLD gathering in San Francisco are from Phase II studies, which tend to be smaller than Phase III studies (the clinical trials the U.S. Food and Drug Administration are generally most interested in when deciding whether or not to approve a new drug). What's really important about Phase II studies is that they provide pharmaceutical companies and researchers a broad sense of how well a new drug works and help everyone decide what to focus on in Phase III studies, which need to be very, very expensive and need to be extremely strict in their design.

You guys are right -- the 100% SVR (cure) rate in the interferon-free patients in the PSI-7977 study only reflects ten of 40 people in the trial. Obviously, no drug or unique combination of drugs should even consider being approved based on such small numbers. But the findings are clearly significant enough to pave the way for larger Phase III studies exploring the potential of interferon-free treatment, which is exactly what Pharmasset is doing now. It's a gamble on the company's part, to be sure, but Pharmasset -- and clearly many who saw the data presented in San Francisco -- will be quick to point out that the Phase II data are compelling enough to place their bets.

Tim Horn 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.